Recent News

• 10.28.2026 - Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development
• 10.27.2026 - Coherus to Participate in Upcoming Investor Conferences
• 10.26.2026 - Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
• 10.14.2026 - Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
• 09.23.2026 - Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
• 08.31.2026 - Coherus to Participate in Upcoming Investor Conferences
• 08.17.2026 - Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
• 08.05.2026 - Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
• 07.22.2026 - Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
• 06.23.2026 - Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

Recent Filings

• 10.29.2026 - 8-K Current report
• 10.29.2026 - EX-99.1 EX-99.1
• 08.28.2026 - 8-K Current report
• 08.28.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 08.28.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 08.17.2026 - 8-K Current report
• 08.17.2026 - 8-K Current report
• 08.17.2026 - EX-99.1 EX-99.1
• 08.05.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 08.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]